Ameliorating Potential of Marketed Formulations Containing Prebiotics And Probiotics Against Carbon Tetrachloride-Induced Hepatotoxicity in rats

Year 2023, Volume: 43 Issue: 3, 212 - 220, 01.09.2023

Dr Gopi Shah , Punitkumar Bhatt , Bhanubhai N. Suhagıa Bharat G. Patel Gaurang B. Shah

https://doi.org/10.52794/hujpharm.1134688

Abstract

In the current study, two marketed formulations VELGUT® (combination of prebiotic and probiotics) and VIZYLAC® (probiotic only) were assessed for a protective effect against carbon tetrachloride (CCl4) induced chronic liver injury model in rats. Rats were randomly divided into four groups. The normal control group was treated with normal saline (C1) and CCl4 treated group was treated with 1 ml/kg intraperitoneal injection of CCl4 one time a day for 10 days followed by two times in a week for 49 days (C2). Test groups composed of the oral treatment of VELGUT (1 mg kg-1) along with CCl4 (T1) and oral treatment of VIZYLAC (4 mg kg-1) along with CCl4 (T2). At the end of the treatment, various serum biochemical parameters like alanine aminotransferase (ALT), aspartate aminotransferase, (AST), alkaline phosphatase (ALP), direct bilirubin, total protein, and albumin levels were measured. Serum AST, ALT, ALP, and direct bilirubin of the groups T1 and T2 were found to be significantly lower as compared to group C1. The level of total protein and albumin was improved in the groups T1 and T2. The level of MDA, glucose and cholesterol was significantly decreased (p<0.05) in the groups T1 and T2 as compared to group C2.

Keywords

liver fibrosis, lipid peroxidation, oxidative stress, liver biomarkers, probiotics

References

• 1. Banrida W, Juliane IB, Heather BC, Heather J. Bellis J, Cameron FK, Craig JM, Matt CC: Toxicant-associated Steatohepatitis. Toxicologic Pathology 2013, 41:343-360.
• 2. Cave M, Falkner KC, McClain CJ: Occupational and Environmental Liver Disease. In Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier Saunders; Philadelphia, 2011, 476–492.
• 3. Renner H: The limited relevance of models used for testing human hepatic diseases and their prevention. In: Keppler E, Popper H, Bianchi L, and Reutter W (Eds.): Mechanisms of Hepatocyte Injury and Death, MTP Press Ltd.; Lancaster, 1985.
• 4. Kaplowitz NTY, Simon FR, Stolz A: Drug induced hepatotoxicity. Annals of Internal Medicine 1986, 104: 826-839. 5. Cotran RS, Kumar V, Robbins SL: Genetic Disorders. In: Cotran RS, Kumar V, Robbins SL: Pathologic Basis of Disease, W. B Saunders Co; Philadelphia, 1994.
• 6. Bigoniya P, Singh CS, Shukla A: A Comprehensive Review of Different Liver Toxicants Used in Experimental Pharmacology. International Journal of Pharmaceutical Sciences and Drug Research 2009, 1(3): 124-135.
• 7. Kanchana N, Sadiq AM: Hepatoprotective effect of Plumbago zeylanica on paracetamol induced liver toxicity in rats. International Journal of Pharmacy and Pharmaceutical Sciences 2011, 3:151-154.
• 8. Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, Churchill T, Madsen K: Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007, 46(3):841–850.
• 9. Chávez-Tapia NC, González-Rodríguez L, Jeong MS, López-Ramírez Y, Barbero-Becerra V, Juárez-Hernández E, Romero-Flores JL, Arrese M, Méndez-Sánchez N, Uribe M: Current evidence on the use of probiotics in liver diseases. Journal of Functional Foods 2015, 17:137–151.
• 10. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M: Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42:675-682.
• 11. Lambert JC, Zhou Z, Wang L, Song Z, McClain CJ, Kang YJ: Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. Journal of Pharmacology and Experimental Therapeutics 2003, 305(3):880-886.
• 12. Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136(1): 65–80.
• 13. Lata J, Jurankova J, Kopacova M, Vitek P: Probiotics in hepatology. World Journal of Gastroenterology 2011, 17(24):2890–2896.
• 14. Nanji AA, Khettry U, Sadrzadeh SM: Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proceedings of the Society for Experimental Biology and Medicine 1994, 205:243-247.
• 15. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM: Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
• 16. Bang CS, Hong SH, Suk KT, Kim JB, Han SH, Sung H, Kim EJ, Kim MJ, Kim MY, Baik SK, Kim DJ: Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhusvernicifera Stokes), and probiotics (Lactobacillus rham R0011 and Lactobacillus acidophilus R0052) on the gut liver axis of alcoholic liver disease. Journal of Ginseng Research 2014, 38:167-172.
• 17. Wang Y, Li Y, Xie J, Zhang Y, Wang J, Sun X, Zhang H: Protective effects of probiotic Lactobacillus casei Zhang against endotoxin- and D-galactosamine-induced liver injury in rats via anti-oxidative and anti-inflammatory capacities. International Immunopharmacology 2013, 15:30-37.
• 18. Fooladi A. Hosseini H, Nourani M, Khani S, Alavian S: Probiotic as a Novel Treatment Strategy Against Liver Disease. Hepatitis Monthly 2013, 13(2):e7521.
• 19. Adeneye AA, Ajagbonna OP, Adeleke TI, Bello SO: Preliminary toxicity and phytochemical studies of the stem bark aqueous extract of Musanga cecropioides in rats. Journal of Ethnopharmacology 2006, 105: 374-379.
• 20. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Sterretz K, Tacke F, Tolba R, Trautwein C, Trebicka J, Weiskries R: Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis & Tissue Repair 2013, 6:19.
• 21. Williams AT, Burk RF: Carbon tetrachloride hepatotoxicity: an example of free radical-mediated injury. Seminars in Liver Disease 1990, 10:279–284.
• 22. Reynolds ES: Liver parenchymal cell injury. Journal of Cell Biology 1963, 19:139–157.
• 23. Ramadori G, Saile B: Portal tract fibrogenesis in the liver. Laboratory Investigation 2004, 84:153–159.
• 24. Tobias A: Mechanism of Probiotic action: A Review. International Journal of Medical Microbiology 2010, 300:57-62.
• 25. Wohlgemuth S, Loh G, Blaut M: Recent developments and perspectives in the investigation of probiotic effects. International Journal of Medical Microbiology 2010, 300(1):3-10.
• 26. Fooa N, Lina S, Leea Yu, Wud M, Wanga Y: Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TG. Toxicology 2011, 282:39–46.
• 27. Kozlov AV, Gille L, Staniek K, Nohl H: Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Archives of Biochemistry and Biophysics 1999, 363:148–154.
• 28. Blease K, Chen Y, Hellewell PG, and Burke-Gaffney A: Lipoteichoic acid inhibits lipopolysaccharide-induced adhesion molecule expression and IL-8 release in human lung microvascular endothelial cells. Journal of Immunology 1999, 163:6139–6147.
• 29. Park JE, Lee DK, Kim KT, Seo JG, Chung MJ, Ha NJ, Park JB, Kim K: Hepatoprotective effects of dual-coated and uncoated mixture of probiotics in rats. Biotechnology & Biotechnological Equipment 2015, 29(6): 1164-1168.